Shutterstock
Close Authorship
As corporate sustainability goes mainstream, ESG reporting is being embraced beyond early adopters exuding good citizenship. Investors, markets and regulators are picking up on the value of environmental, social and governance data, which is being integrated more often into financial disclosures. People have realized that sustainability disclosure and sustainability information has significant value, said Janine Guillot, CEO of the standards-setter SASB (Sustainability Accounting Standards Board).
Soon, more companies will be forced to divulge environmental and social data, whether due to new laws and regulations, investor demands or simply to remain relevant and competitive, experts shared at the GreenFin 21 virtual event Tuesday.
Rincon Resources Pty Ltd ( Rincon ) The Company advised in late June 2020 that it had invested AUD$250,000 (approximately £140, 000) in Rincon, an Australian gold and base metals exploration company. At the time the Company s investment represented approximately 28% of Rincon s issued share capital. Rincon is a Western Australian ( WA ) focused gold and base metals company which holds a 100% interest in three highly prospective projects in WA; the South Telfer, Laverton and Kiwirrkurra Projects. Each project has been subject to historical exploration which has identified large outcropping mineralised systems. Rincon intends to explore the projects in order to delineate copper and gold resources. It intends to drill these three projects during the first half of 2021.The main focus is on the South Telfer Project, covering 50,000 hectares in the Paterson province. The South Telfer Project is approximately 12km south of Newcrest
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Affimed N.V.April 15, 2021 GMT
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL
AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses
AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021
AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapy
Bertrand Perrin appointed as IASB member theaccountant-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaccountant-online.com Daily Mail and Mail on Sunday newspapers.